Natriuretic Peptides and Assessment of Cardiovascular Disease Risk in Asymptomatic Persons

被引：10

作者：

Daniels L.B. ^{[1
]}

机构：

[1] Division of Cardiology, University of California, San Diego, La Jolla, CA, 92037-1300, MC 0986, 9350 Campus Point Drive

来源：

Current Cardiovascular Risk Reports | 2010年 / 4卷 / 2期

关键词：

Natriuretic peptides; Primary prevention; Risk assessment; Screening;

D O I：

10.1007/s12170-010-0078-8

中图分类号：

学科分类号：

摘要：

Current tools for cardiovascular disease (CVD) risk assessment in asymptomatic individuals are imperfect. Preventive measures aimed only at individuals deemed high risk by current algorithms neglect large numbers of low-risk and intermediate-risk individuals who are destined to develop CVD and who would benefit from early and aggressive treatment. Natriuretic peptides have the potential both to identify individuals at risk for future cardiovascular events and to help detect subclinical CVD. Choosing the appropriate subpopulation to target for natriuretic peptide testing will help maximize the performance and the cost effectiveness. The combined use of multiple risk markers, including biomarkers, genetic testing, and imaging or other noninvasive measures of risk, offers promise for further refining risk assessment algorithms. Recent studies have highlighted the utility of natriuretic peptides for preoperative risk stratification; however, cost effectiveness and outcomes studies are needed to affirm this and other uses of natriuretic peptides for cardiovascular risk assessment in asymptomatic individuals. © 2010 The Author(s).

引用

页码：120 / 127

页数：7

共 65 条

[61]

Schroder F., Kattan M.W., The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review, Eur Urol, 54, pp. 274-290, (2008)

[62]

Swets J.A., Getty D.J., Pickett R.M., Et al., Enhancing and evaluating diagnostic accuracy, Med Decis Making, 11, pp. 9-18, (1991)

[63]

Fahey M.T., Irwig L., Macaskill P., Meta-analysis of Pap test accuracy, Am J Epidemiol, 141, pp. 680-689, (1995)

[64]

Pencina M.J., D'Agostino S.R.B., D'Agostino Jr. R.B., Vasan R.S., Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond, Stat Med, 27, pp. 157-172, (2008)

[65]

Hlatky M.A., Greenland P., Arnett D.K., Et al., Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association, Circulation, 119, pp. 2408-2416, (2009)

← 1 2 3 4 5 6 7 →